Home > Boards > US Listed > Biotechs >

Spero Therapeutics, Inc. (SPRO)

Add SPRO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 11/17/2020 10:17:37 PM - Followers: 2 - Board type: Free - Posts Today: 0


Our Aim Is to Identify, Develop and
Commercialize Novel Treatments for
Multi-Drug Resistant Bacterial Infections and Rare Disease

  • Spero Therapeutics is a global, multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. Our mission is to become a leader in the field of Gram-negative antibiotics and we aim to achieve this objective by advancing multiple, differentiated products towards commercialization in key territories.

Hope Is at the Core of Our Mission

Spero Therapeutics is highly committed to advancing novel treatment approaches for bacterial infections with a world-class team of biotechnology and biopharmaceutical experts. At Spero Therapeutics, we embrace the Italian word “spero,” which means “hope.” Spero’s mission as the leader in the field of antibiotic drug development is to give hope to patients afflicted with drug resistant infections by developing transformative anti-infective medicines.

As we strive to combat the high unmet medical need associated with drug-resistant bacterial infections, our most advanced product candidate, tebipenem HBr, is designed to be the first oral carbapenem-class antibiotic for use in adults to treat multi-drug resistant (MDR) Gram-negative infections. In September 2020, we announced positive Phase 3 data for tebipenem HBr for the treatment of complicated urinary tract infection (cUTI).  If approved by the FDA, tebipenem HBr would be the first oral cUTI drug to earn approval in 26 years, which would be an important achievement given the high levels of resistance to currently available oral therapies. Treatment with effective orally administered antibiotics may help avoid hospitalization and in hospital setting it may help accelerate hospital discharge by delivering a more convenient and cost-effective treatment for patients.

We are also developing SPR720, an oral antibacterial agent currently under development for the treatment of non-tuberculous mycobacterial (NTM) disease, a rare orphan disease.

Additionally we have a platform technology known as our Potentiator Platform.  Our product candidate from this platform, SPR206, is an IV-administered agent being developed as an innovative option to treat MDR Gram-negative bacterial infections.

Founded in 2013, and named as one Boston’s Best Places to Work in 2020 and 2017 by the Boston Business Journal, Spero Therapeutics is also the recipient of the first-ever 2017 Xconomy Startup of the Year Award. We sincerely believe that our novel product candidates will have meaningful impact on patient health and significant commercial applications for the treatment of MDR infections in both the hospital and community settings.


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SPRO News: Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, Mar... 03/03/2021 08:30:00 AM
SPRO News: Spero Therapeutics to Present at Investor Conferences in March 02/25/2021 08:30:00 AM
SPRO News: Amended Statement of Beneficial Ownership (sc 13d/a) 02/16/2021 05:40:14 PM
SPRO News: Amended Statement of Ownership (sc 13g/a) 02/16/2021 04:01:37 PM
SPRO News: Amended Statement of Ownership (sc 13g/a) 02/16/2021 06:30:16 AM
Consent Preferences